Issue link: http://osercommunicationsgroup.uberflip.com/i/365686
C h a i n D ru g s to re D a i l y 6 1 Tu e s d a y, Au g u s t 2 6 , 2 0 1 4 creams and ointments. With in-depth industry experience, its management team has begun leading the TAGI Pharma emergence, focusing on sales and marketing, product acquisition and product development activities. With an established presence in the U.S. market, led by the drive of its manage- ment team and accomplished by the dedication and efforts of intercompany synergy, TAGI will continue its soar to new heights. Differentiators TAGI's strength is derived from its understanding of the market and identifi- cation of product opportunities. Its mar- keting mix utilizes various platforms compounded into the TAGI formulation. Its product quality and high service levels drive performance. Its current and still expanding product portfolio consists of 10 product families with 17 SKU's. Our portfolio is built through licensing, acquisition and development initiatives. A full pipeline keeps a constant flow of new product launches. TAG I Pharma ( Cont'd. from p. 1) Product Portfolio Alendronate Sodium Oral Solution 70mg/75mL: Only oral solution/generic alternative to tablets. Astringent Solution Powder Packets: Generic to Bayer's Domeboro ® with con- sumer coupons (GCN# 31828). Benzoyl Peroxide Emollient Foam: 3 SKU's with consumer coupons (GCN# 27596 & 29303). Nivatopic Plus Cream: 2014 launch with consumer coupons (GCN# 30324). Flavoxate Hydrochloride 100mg Tablets, Codeine Sulfate Oral Solution (CII) 30mg/5mL, Hydromorphone Hydrochloride 8mg Tablets, USP (CII), Naltrexone Hydrochloride 50mg Tablets, USP, Phentermine Hydrochloride 37.5mg Tablets, USP (CIV), and Phentermine Hydrochloride 15mg and 30mg Capsules, USP (CIV). Please visit www.tagipharma.com to view its com- plete product listings and full prescribing information which includes indications for use and additional important safety information. Visit TAGI Pharma at booth 1725. abuse issue is being implemented by the DEA: pursue the wholesalers, retailers and prescribers (among other stake- holders) involved in the distribution, dispensing and prescribing of con- trolled substances that may be intended for misuse. As a result, some distribu- tion centers are experiencing suspen- sion of their DEA licenses, some retail stores dispensing controlled substances written by a certain prescriber or for an individual patient are having their licenses to dispense these products revoked, prescribers writing excessive- ly and inappropriately for controlled substances are being arrested and losing their licenses, and other stakeholders are incurring significant fines and suf- fering public relation gaffes. The Need for Information One dilemma underlying this approach: how does a stakeholder know which orders or prescriptions are normal and which are out of standard bounds? Mining and analyzing internal informa- tion may help, but it will never tell the whole story. Without the ability to bench- mark these orders against the total mar- ketplace or know which scripts are being filled outside of your stores for a certain prescriber, the inferences made off of internal data may be misleading. Partial knowledge, in this case, can be a danger- ous thing. In addition, these benchmarks need to be accurate, timely and specific IMS Health ( Cont'd. from p. 1) to the situation. For example, what are the total volumes and trends in the local geography and how do they impact the analysis? How do the prescribing pat- terns of a physician differ compared to doctors with similar profiles? Is this store getting controlled substances from multi- ple warehouses, thus creating an abnor- mal level of inventory? Having the right answers to these questions may help members of the distribution chain thwart illicit use of controlled substances and thus contribute to curtailing this alarming societal problem. IMS Health is committed to helping pharmacies and wholesalers make dis- pensing decisions that are both informed and expedited. Using data assets that span the nation and reflect (1) physician prescribing patterns, (2) current supply at the outlet level, (3) anonymized and longitudinal patient information, (4) dis- pensing data, and (5) stakeholder pro- files, IMS creates an end-to-end picture of controlled substances from supply through demand within local market- places. Utilizing this information can help pharmacies and wholesalers detect outlier activities, and focus their inves- tigative efforts to keep the supply lines open for proper use while potentially ebbing inappropriate behaviors. For more information, contact IMS Health at 610-244-2572 or coloughlin@us.imshealth .com, go to www.imshealth.com or stop by booth 608. Anda provides our manufacturer and retailer partners with customized supply chain programs and exceptional service. CDD: What would you say makes your company unique? BV: Anda's position as the premier next- day small-box distributor of pharmaceu- ticals, and our strength in customizing programs to support our customer needs, has given us access to nearly every phar- macy in the country. Our distribution services can be as basic or sophisticated as needed based on our manufacturer and customer partner's goals. Additionally, we have developed a wide variety of technology solutions, such as CSOS, automated out-of-stocks, customized web portals and more, that provide a user-friendly interface for our customers to place their orders and improve service levels. CDD: Where is your current product emphasis? BV: While Anda has always been focused on generic pharmaceuticals, we are also actively selling a broad portfolio of branded and specialty Rx products, as well as OTC and Animal Health prod- ucts, which create incremental margin opportunities for our vendor and retailer partners. Anda currently carries over 200 specialty branded SKUs and services ANDA ( Cont'd. from p. 1) other niche product opportunities that are customizable to meet specific customer goals. CDD: How do you handle sales? BV: Anda's sales model is as customiz- able as the programs we offer. Our cus- tomers have the ability to leverage our corporate accounts team, technology platforms or inside sales team to create the type of customer experience that they desire when purchasing their pharmaceu- tical products. This personalized support gives Anda a unique footprint in the phar- maceutical supply chain. CDD: To what do you attribute your company's success? BV: Our company's success is very much driven by our creativity and com- mitment to quality. As an organization, we thrive on the opportunity to create new ways to improve our customer experience, leveraging our manpower and technology to create solutions to distribution challenges in the market- place. The hard work and dedication that goes into everything we do is visi- ble in the products and services we deliver. I am very proud of our ability to partner to create solutions for our cus- tomers and our willingness to accept challenging opportunities. For more information, visit booth 2041, call 800-331-ANDA (2632) or go to www.andanet.com. marketing promotions in order to increase brand awareness and product recognition and heighten customer loyalty." First-Ever Television Commercial Earns Rave Reviews The company made a bold move for Valentine's Day 2014 with its first-ever 60-second television commercial for Gun Oil that told the homecoming story of a married gay soldier and his partner. The spot aired in seven major U.S. markets on the Bravo and E! networks. The video also was promoted on YouTube, where it instantly went viral and has been viewed almost 400,000 times. Adweek.com, a leading voice of the advertising business, said about the com- mercial: "The Year's Most Provocative Valentine's Day Ad Is Also One of Its Empowered Products ( Cont'd. from p. 4) Most Touching." The ad can be viewed by visiting www.gunoil.com. Empowered Products also launched in late 2013 a new online Wellness Store in the United Kingdom, offering its full lubricant product line to that market. Fraser said the company will continue to exhibit its prod- ucts at trade shows around the world and devote additional resources into print and radio advertising to promote its brands. Empowered Products develops, manufactures, markets and sells 17 SKUs in two product lines: PINK for women, and Gun Oil for men, all of which are Made in USA. Visit Empowered Products at booth 1565. For more information, go to www.empoweredproducts.com, call 800- 929-0407 or email wholesale@em poweredproducts.com. any amount, even for a short period of time. Potentially any fetus exposed dur- ing pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affect- ed. Because of this toxicity, isotretinoin can only be marketed under a special restricted distribution program. This pro- gram is called iPLEDGE™. Under this program, prescribers must be registered and activated with the iPLEDGE pro- gram and can prescribe isotretinoin only to registered patients who meet all the requirements of iPLEDGE. Isotretinoin can be dispensed only by a pharmacy registered and activated with iPLEDGE. Registered and activated pharmacies can only receive isotretinoin from whole- salers registered with iPLEDGE. Patients on isotretinoin have been known to become depressed or to devel- op other serious mental health prob- lems. Some people have had thoughts of hurting themselves or putting an end to their own lives. Some people tried to end their own lives and some have ended their own lives. There have been reports that people on isotretinoin were aggressive or violent. No one knows if isotretinoin caused these problems or Ranbaxy ( Cont'd. from p. 4) behaviors or if they would have hap- pened even if the person did not take isotretinoin. Isotretinoin use has been associated with pseudotumor cerebri, a condition caused by increased pressure on the brain. This condition may occur more often in patients also taking tetracy- cline. Patients should be aware of other serious side effects, including problems with the skin, pancreas, liver, stomach, bones, muscles, hearing, vision, lipids, allergic reactions, blood sugar or red and white blood cells. The most com- mon, less serious adverse events include dry skin, chapped lips, dry eyes and dry nose that may lead to nose- bleeds. Patients should be advised about these adverse events and routine- ly monitored by a doctor during treat- ment with isotretinoin. Isotretinoin has been associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. In some instances, symptoms have been reported to persist after isotretinoin treatment has been stopped. Visit Ranbaxy at booth 2316. For more information, call 888-RANBAXY or go to www.ranbaxy.com.